nivolumab ipilimumab

Details

Files
Generic Name:
nivolumab ipilimumab
Project Status:
Pending
Therapeutic Area:
Melanoma
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0371-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A​
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
​Indicated in neoadjuvant setting for resectable stage III melanoma.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.